Cytokinetics, Inc. (CYTK) Posts Q2 Loss of 23c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500, Nasdaq set for higher open as investors weigh weaker oil, PPI data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth
July 31, 2014 2:17 PM EDTRoth Capital reaffirms its Buy rating and $13 price target on Cytokinetics (Nasdaq: CYTK) following the company's Q2 report.
Ahead of the bell, Cytokinetics posted Q2 loss of $0.23 per share with revenue of $7.8 million, versus consensus estimates calling for a loss of $0.32 per share and revs of $7.0 million. Roth was looking for a loss of $0.38 per share and revenue of $4.0 million.
Roth analyst Joseph Pantginis... More
